# FDA Approves APPCO's Generic Drug Application APPCO has received FDA approval for an abbreviated new drug application (ANDA 220329), expanding its generic pharmaceutical portfolio and positioning the company to capture market share in an established therapeutic segment. The approval is expected to enhance APPCO's competitive standing and provide cost-effective treatment options to patients and healthcare systems.